30 completed. 30 Phase 2, 6 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 30 |
| Phase 1 | 6 | Completed 6 |
| Phase 3 | 4 | Completed 4 |
Follow Benign Prostatic Hyperplasia: new trials by email Literature Review of Benign Prostatic Hyperplasia trials Research Report on Benign Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility Spermotrend - Male Infertility, Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | Catalysis SL | 150 | 2021-06-15 | 2023-03-28 |
| Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia Composite Steep-pulse Treatment Device, Tamsulosin Hydrochloride Capsules - Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | REMD Medical Technology | 160 | 2020-08-20 | 2022-09-07 |
| The Effect of Traditional Chinese Medicine on Benign Prostatic Hyperplasia VGH-BPH1, Placebo (Corn starch pill manufactured to mimic VGH-BPH1) - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | Taipei Veterans General Hospital, Taiwan | 23 | 2019-03-06 | 2020-04-13 |
| Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter Optilume™ BPH Prostatic DCB Dilation Catheter, Paclitaxel - Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy | Phase 2 | Completed | Urotronic Inc. | 80 | 2017-12-19 | 2025-11-26 |
| A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia talaporfin sodium, Saline, Drug Activator 100 J/cm - Benign Prostatic Hyperplasia | Phase 2 | Completed | Light Sciences Oncology | 225 | 2014-11-01 | 2018-08-08 |
| Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia WC3055, Placebo - Benign Prostatic Hyperplasia | Phase 2 | Completed | Warner Chilcott | 796 | 2013-08-01 | 2015-06-29 |
| Prostate Embolization for Benign Prostatic Hyperplasia Prostatic Embolization with Embosphere Micropsheres - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | James B. Spies, MD | 15 | 2013-08-01 | 2019-12-10 |
| Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD), Doxazosin 4 mg every day (QD) - Benign Prostatic Hyperplasia | Phase 2 | Completed | Buddhist Tzu Chi General Hospital | 140 | 2012-08-01 | 2014-07-15 |
| Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS onaBoNT-A + placebo, Tamsulosin + placebo - Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms | Phase 2 | Completed | VA Office of Research and Development | 63 | 2012-06-01 | 2021-10-05 |
| Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) PRX302, Placebo - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | Sophiris Bio Corp | 40 | 2011-09-01 | 2013-08-21 |
| Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia botulinum toxin Type A, Normal saline - Benign Prostatic Hyperplasia | Phase 2 | Completed | Allergan | 315 | 2010-08-01 | 2019-05-03 |
| MCS in the Treatment of Lower Urinary Tract Symptoms MCS-2 15 mg/day, MCS-2 30 mg/day, Placebo - Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | Health Ever Bio-Tech Co., Ltd. | 274 | 2010-07-01 | 2015-03-03 |
| A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia Botulinum Toxin Type A, Placebo (saline) - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | Allergan | 61 | 2009-08-01 | 2013-09-30 |
| Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia S-equol, Placebo - Benign Prostatic Hyperplasia | Phase 2 | Completed | Ausio Pharmaceuticals, LLC | 116 | 2009-06-01 | 2017-05-19 |
| Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) talaporfin sodium, Transurethral illumination with light emitting diodes, Placement - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 2 | Completed | Light Sciences Oncology | 21 | 2009-05-01 | 2012-11-16 |
| Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia PRX302, Placebo - Benign Prostatic Hyperplasia | Phase 2 | Completed | Sophiris Bio Corp | 92 | 2009-01-01 | 2018-11-21 |
| Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension Tadalafil 2.5 mg, Tadalafil 5 mg, Placebo - Benign Prostatic Hyperplasia | Phase 2 | Completed | Eli Lilly and Company | 422 | 2008-11-01 | 2011-03-29 |
| Efficacy of Natural Extract 2007RD01 Combined With Saw Palmetto in Benign Prostatic Hyperplasia Patients Compared to Saw Palmetto Combination of 2007RD01 and saw palmetto lipidic extract, Saw palmetto lipidic extract - Benign Prostatic Hyperplasia | Phase 2 | Completed | innoVactiv Inc. | 110 | 2008-11-01 | 2011-04-13 |
| Efficacy Study of HoLEP and TURP on LUTS Secondary to BPH Transurethral resection of the prostate, Holmium Laser Enucleation of the Prostate - Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia | Phase 2 | Completed | Samsung Medical Center | 313 | 2008-10-01 | 2019-12-02 |
| Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men Tadalafil, Placebo, Tamsulosin - Benign Prostatic Hyperplasia | Phase 2 | Completed | Eli Lilly and Company | 151 | 2007-10-01 | 2010-11-25 |
Showing 20 of 30. Sign in to see all of them.
Prostatic Hyperplasia (30) · Lower Urinary Tract Symptoms (5) · Genital Diseases (1) · Infertility, Male (1) · Prostatic Diseases (1) · Prostatitis (1)
Genital Diseases, Male (30) · Male Urogenital Diseases (30) · Urogenital Diseases (30) · Genital Diseases (29) · Prostatic Diseases (29) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Urological Manifestations (5) · Infertility (1)
Botulinum Toxins, Type A (5) · Tadalafil (4) · Tamsulosin (3) · PRX302 (2) · Saline Solution (2) · Sodium Chloride (2) · Talaporfin (2) · Celecoxib (1) · Doxazosin (1) · Drug Implants (1) · Dutasteride (1) · Equol (1) · Ethanol (1) · Paclitaxel (1) · Photochemotherapy (1)
Eli Lilly and Company (4) · Allergan (3) · Light Sciences Oncology (2) · Sophiris Bio Corp (2) · American Medical Systems (1) · Ausio Pharmaceuticals, LLC (1) · Bayer (1) · Buddhist Tzu Chi General Hospital (1) · Catalysis SL (1) · GlaxoSmithKline (1) · Health Ever Bio-Tech Co., Ltd. (1) · James B. Spies, MD (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · QLT Inc. (1)
United States (14) · Canada (5) · South Korea (4) · Germany (3) · Taiwan (3) · Australia (2) · Czechia (2) · France (2) · Japan (2) · Austria (1) · China (1) · Dominican Republic (1) · Greece (1) · India (1) · Italy (1)
Allan J Pantuck, MD, MS, FACS (1) · Christopher P Smith, MD (1) · Donald Bergner, MD (1) · Hann-Chorng Kuo, M.D. (1) · Herman Ellman, MD (1) · Jill Moland (1) · Kyu-Sung Lee, Ph.D.,M.D. (1) · Lisa Koch-Hulle (1) · Mostafa Elhilali, MD (1) · Peter Pommerville, MD (1)
PMID 21791356, PMID 15126771, PMID 18461049, PMID 18722631, PMID 19409693, PMID 20163842, PMID 23098762, PMID 26299520, PMID 37354260
U01DK060817 (1)